Simcere's Endu Becomes First Drug To Complete Phase IV Trials Under New Drug Registration Regs

SHANGHAI- Simcere Pharmaceutical Group, a leading Chinese pharmaceutical and biotech firm, announced March 22 that its biopharmaceutical Endu (recombinant human endostatin injection) for non-small cell lung cancer (NSCLC) has completed Phase IV clinical trials and became the first drug to pass re-registration procedures outlined by China's State FDA